论文信息 - Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.

Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.

8026 Background: Platinum doublets provide 6-mo PFS and 12-mo OS for treatment-naive, metastatic NSCLC without driver mutations. Preliminary data from KEYNOTE-001 revealed robust antitumor activity...